Statin myopathy as a metabolic muscle disease

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 7, 2008, Pages 971-978

  Phillips, Paul S ^a   Haas, Richard H ^b  

^a SCRIPPS MERCY HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Metabolism; Myopathy; Rhabdomyolysis; Statin; Toxicity

Indexed keywords

3 METHYLGLUTACONIC ACID; ADENOSINE MONOPHOSPHATE DEAMINASE; ALCOHOL; ANTIRETROVIRUS AGENT; ATORVASTATIN; ATYPICAL ANTIPSYCHOTIC AGENT; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; CORTICOSTEROID; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLYCOGEN PHOSPHORYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; OROTATE MAGNESIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; PRAVASTATIN; PROTEASOME; PROTEIN KINASE B; SIMVASTATIN; SOMATOMEDIN C; UBIDECARENONE; UBIQUITIN; UNINDEXED DRUG; FATTY ACID;

AEROBIC METABOLISM; ALCOHOL CONSUMPTION; AMYOTROPHIC LATERAL SCLEROSIS; CARNITINE DEFICIENCY; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSLIPIDEMIA; EXERCISE; FATTY ACID OXIDATION; GENE MUTATION; GLUCOSE INTOLERANCE; GLYCOGEN STORAGE DISEASE TYPE 5; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LIPID OXIDATION; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE HYPERTROPHY; MUSCLE METABOLISM; MUSCLE STRESS; MYALGIA; NONHUMAN; OBESITY; PATHOGENESIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TOXIC MYOPATHY; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; RISK FACTOR;

FATTY ACIDS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; OXIDATION-REDUCTION; RHABDOMYOLYSIS; RISK FACTORS;

EID: 52049084855     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.7.971     Document Type: Review

References (44)

1. Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12, 777-785 (2007).
2. Lofberg M, Jankala H, Paetau A, Harkonen M, Somer H. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol. Scand. 98, 268-275 (1998).
3. Vladutiu GD, Simmons Z, Isackson PJ et al. Genetic risk factors associated with hpid-lowering drug-induced myopathies. Muscle Nerve 34, 153-162 (2006).
4. Bank WJ, DiMauro S, Bonilla E, Capuzzi DM, Rowland LP. A disorder of muscle lipid metabolism and myoglobinuria. Absence of carnitine patmityl transferase. N. Engl. J. Med. 292, 443-449 (1975).
5. Kaufmann P Török M, Zabno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol. Life Sci. 63, 2415-2425(2006).
6. Wagner BK, Kitami T, Gilbert TJ et al. Large-scale chemical dissection of mitochondrial function. Nat. Biotechnol. 26, 343-351 (2008).
7. Velho JA, Okanobo H, Degasperi GR et al. Statins induce calcuim-dependent mitodiondrial permeability transition. Toxicology 219, 124-132 (2006).
8. Hanai J, Cao P, Taksale P et al. The muscle-specific ubiquitin ligase, atrogin-1/MAFbx mediates toxicity from HMG CoA reducuse inhibitors. J. Clin. Invest. 117, 3940-3951 (2007).
9. Phillips PS, Haas RH, Barshop B, Bannykh S, Amjadi D. Utility of abnormal 3-methylglutaconic aciduria (3MGA) in diagnosing statin associated myopathy. [abstract]. Atheroycler. Thromb. Vasc. Biol. 22, 878 (2002).
10. Phillips PS, Haas RH, Bannykh S et al.; The Scripps Mercy Clinical Research Center. Statin associated myopathy with normal creatine kinase. Ann. Int. Med. 137, 581-585 (2002).
11. Truong TH, Moran, R, Laaksonen R et al Muscle characteristics in statin myotoxicity. J. Am. Coll. Cardiol. 51, A326 (2008) (Abstract).
12. Paiva H, Thelen KM, Van CR et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin. Pharmacol. Ther. 78, 60-68 (2005).
13. Schick BA, Laaksonen R, Frohlich JJ et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin. Pharmacol. Ther. 81, 650-653 (2007).
14. Scheller K, Seibel P, Sekeris CE. Glucocorticoid and thyroid hormone receptors in mitochondria of animal cells. Int. Rev. Cyt. 222, 1-61 (2003).
15. Duntas LH. Review - thyroid disease and lipids. Thyroid 12, 287-293 (2002).
16. Kordas KC, Phillips PS, Golomb BA. Clinical characteristics of 1053 patients with statin associated muscle complaints. Artheroscler. Thromb. Vasc. Biol. 24, E51-E136 (2004) (Abstract).
17. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr. Opin. Clin. Nutr. Metab. Care. 4, 183-190 (2001).
18. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl Acad. Sci. USA 98, 14440-14445 (2001).
19. Phillips PS, Phillips CT, Sullivan M, Naviaux RK, Haas RH and the Scripps Mercy Clinical Research Center. Statin myotoxicity is associated with changes in cardiopulmonary function. Atherosclerosis 177, 183-188 (2004).
20. Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol. Path. 33, 246-257 (2005).
21. Thompson PD, Nugent AM, Herbert PN. Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors. JAMA 264, 2992 (1990).
22. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc. Drugs Ther. 17, 459-465 (2003).
23. Sinzinger H, O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clin. Pharmacol. 57, 525-528 (2004).
24. Urso MI, CJarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Aterioscler. Thromb. Vasc. Biol. 25, 2560-2566 (2005).
25. Paolisso G, Barbagallo M, Petrella G et al. Effects of siravastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150, 121-127 (2000).
26. Moran R, Truong T, Wolfson T, McDonald FG, Phillips PS. Utility of cardiopulmonary exercise to assess myopathy [abstract]. Arterioscler. Thromb. Vasc. Biol. (2008) (In Press).
27. Barker BJ, Goodenough RR, Falko JM. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 26, 2482-2483 (2003).
28. Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am. J. Med. 86, 481-483 (1989).
29. Havranek JM, Wolfsen A, Warnke GA, Philips PS. Monotherapy with ezetimibe causing myopathy. Am. J. Med. 119, 285-286 (2006).
30. Durst R, Rund D, Schurr D et al. One year experience with a low density lipoprotein apheresis system. IAMJ 4, 677-680 (2002).
31. Sikand H, Jaojoco J, Linares L, Phillips PS. Risk of death with atypical antipsychotics [letter]. JAMA 295, 495-496 (2006).
32. Lieber CS, Leo MA, Xiaolei W, DeCarli LM. Effect of chronic alcohol consumption on hepatic SIRT1 and PGC-1α in rats. Biochem. Biophys. Res. Com. 370, 44-48 (2008).
33. Cade WT, Reeds DN, Mittendorfer B et al. Blunted lipolysis and fatty acid oxidation during moderate exercise in HIV-infected subjects taking HAART. Am. J. Physiol. Endocrinol. Metab. 292, E812-E819 (2007).
34. Luzi L, Perseghin G, Tambussi G et al. Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 284, E274-E280 (2003).
35. Gaist D, Garcia Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12, 565-569 (2001).
36. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004).
37. Castro Cabezas M, de Bruin TW, de Valk HW et al. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92, 160-168 (1993).
38. Phillips PS, Ciaraldi TP, Kim DL, Verity MA, Wolfen AR, Henry RR. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids [abstract]. J. Am. Coll. Cardiol. 45, 413A (2005).
39. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 30, 515-525 (2007).
40. Dupuis L, Oudart H, René F, Gonzalez de Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc. Natl Acad. Sci. USA 101, 11159-11164 (2004).
41. Fergani A, Oudart H, Gonzalez De Aguilar JL et al. Increased peripheral lipid clearance in an animal model of amyotrophic lateral sclerosis. J. Lipid Res. 48, 1571-1580 (2007).
42. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J. Biochem. Cell Biol. 37, 1974-1984 (2005).
43. Iakoubova OA, Tong CH, Rowland CM et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 51, 435-443 (2008).
44. Iakoubova OA, Sabatine MS, Rowland CM et al. Polymorphism in KIF6 gene and benefit firom statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 51, 449-455 (2008).